Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

NCT ID: NCT04261582

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: SUSPENDED
• Total Enrollment: 245 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-11-06
• Study Completion Date: 2022-04-30

Brief Summary

Aspirin Exacerbated Respiratory Disease (AERD) is a relatively homogeneous disease characterized by adult-onset severe asthma, development of non-cancerous growths in the nasal canal (i.e. nasal polyps) and aspirin allergy. The cause of AERD is unknown, although likely results from environmental insults in combination with genetic susceptibility. AERD disease homogeneity increases the possibility of discovering narrowly-defined genetic contributors, and makes it an ideal population to study the genetic and epigenetic changes that cause asthma. Researchers recently discovered that gene expression of epithelial growth and repair (EGR) genes are substantially decreased in bronchial airway epithelial cells of severe asthmatics compared to less severe asthmatics and healthy controls. This new finding indicates that epithelial integrity and related processes may be of primary importance to the development of severe asthma, and potentially the severe asthma subtype, AERD. This finding was later supported in a subsequent lab model, which showed that blocking a central epithelial repair and differentiation gene, human epidermal growth factor receptor 2 (ERBB2), decreased healing time of bronchial epithelial cells after injury. Thus, the objective of the proposed study is to determine whether EGR gene are also down-regulated in AERD, a homogeneous severe asthma subtype. As an extension, the researchers will also determine whether genetic mutations and/or epigenetic changes relate to and potentially explain this down-regulation of EGR genes. Specifically, the researchers plan to obtain gene expression of freshly brushed nasal airway epithelial cells of 140 AERD patients, 70 non-aspirin sensitive asthma patients, and 35 healthy controls, noting that nasal epithelial gene expression has recently been shown to mirror lung epithelial changes in asthmatic airways. Swabbing the nasal canal for epithelial cells allows to evaluate airway epithelial cell gene expression non-invasively. Our experimental design contrasts AERD gene expression profiles against healthy controls, and determines whether EGR genes are depressed in AERD relative to health controls. As a corollary, the researchers look to discover an AERD-specific gene expression profile which may one-day aid in diagnosis and expand current knowledge of disease mechanisms. As an extension, the researchers will correlate gene expression changes, specifically any finding of down-regulated EGR genes, with methylation changes (i.e. epigenetic changes) and genetic mutations.

Conditions

Aspirin Exacerbated Respiratory Disease; Aspirin-Sensitive Asthma; Nasal Polyps

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

AERD participants

Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.

No interventions assigned to this group

Healthy controls

Healthy participants that do not have asthma.

No interventions assigned to this group

Non-aspirin sensitive asthma participants

Participants with asthma, but that do not have a sensitivity to aspirin.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Physician diagnosis of asthma
• Physician diagnosis of chronic nasal disease featuring nasal polyps
• Sensitivity to aspirin verified by an aspirin provocative challenge in clinic
• Healthy control participant

Exclusion Criteria

• Active smoking
• Pregnancy
• History of greater than or equal to 10 pack-years of smoking
• Any significant comorbid conditions that could inadvertently interfere with study results
• Conditions that require bursts of oral corticosteroids
• Other significant lung diseases
• Other disease in the view of the investigator prohibits participation in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The Scripps Research Institute

OTHER

Sponsor Role: collaborator

National Jewish Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

National Jewish Health

Denver, Colorado, United States

Countries

United States

Other Identifiers

HS-3200sIRB

Identifier Type: -

Identifier Source: org_study_id